FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

Related Categories:

Drug, Bio-affecting And Body Treating Compositions


Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)



Highly concentrated pharmaceutical formulations
03/26/15 - 20150086537 - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of...

Antibody light chains
03/26/15 - 20150086538 - The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid...

Cross-reactive staphylococcus aureus antibody
03/26/15 - 20150086539 - The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as...

Methods of using an antibody to inhibit wnt-mediated cardiac remodeling
03/26/15 - 20150086540 - The present invention is directed to monoclonal antibodies and fragments thereof directed to LRP5/6 that find use in the prevention and treatment of cardiac remodeling and cancer. Also disclosed are methods for using such monoclonal antibodies in the prevention and treatment of such diseases....

Methods of cytotoxic gene therapy to treat tumors
03/26/15 - 20150086541 - A method is disclosed for decreasing or retarding an increase in the size of a localized or metastatic tumor by using a combination of an immune stimulating cytotoxic gene therapy and immune-checkpoint modulating agent, in conjunction with other therapies, including radiation therapy, chemotherapy, surgery, and immunotherapies....

Compositions and methods for the prevention of microbial infections
03/26/15 - 20150086542 - This disclosure provides methods and compositions to inhibit or prevent infection of a cell by a bacteria that exports DNABII proteins by administering to a tissue infected with the bacteria an effective amount of an antibody that specifically recognizes and binds the DNABII proteins, thereby inhibiting or preventing infection of...

Diagnotic markers
03/26/15 - 20150086543 - The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene....

Stabilized liquid anti-rsv antibody formulations
03/26/15 - 20150086544 - The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof,...

Combination therapy of her expressing tumors
03/26/15 - 20150086545 - The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors....

Humanized anti-ccr2 antibodies and methods of use therefor
03/26/15 - 20150086546 - The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of...

Combination therapy for treating breast cancer
03/26/15 - 20150086547 - The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGFβ) antagonist in combination with capecitabine and ixabepilone to treat breast cancer....

Non-catalytic domain targets in matrix metalloprotease proteins for cancer therapies
03/19/15 - 20150079071 - The present invention provides compositions and methods for inhibiting MMPs, especially MMP-3, MMP-9 and MMP-14. The invention relates to the field of diagnostic and prognostic methods of human cancers, especially breast cancer and the field of matrix metalloproteases, as targets for diagnostics and therapeutics....

Assays to monitor bleeding disorders
03/19/15 - 20150079072 - The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample...

Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
03/19/15 - 20150079073 - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone....

Antibody formulations and methods
03/19/15 - 20150079074 - The invention provides antibody formulations and methods useful for prophylaxis or treatment of synucleinopathies, including Parkinson's disease....

Anti-cd11a antibodies and uses thereof
03/19/15 - 20150079075 - Provided herein are isolated human, chimeric, and humanized antibodies and antigen-binding fragments thereof that specifically bind to CD11a. Also provided are methods of treating human immunodeficiency virus (e.g., reducing the risk of developing or preventing the development of HIV infection or AIDS) in a subject that has an HIV infection...

Identification of non-responders to her2 inhibitors
03/19/15 - 20150079076 - The present invention relates to means and methods for the identification of non-responders to a HER2 inhibitor, whereby one or more mutations in exon 9 of Phosphoinositol-3 kinase (PIK3CA) indicate non-responsiveness....

Methods and compositions for therapeutic agents
03/19/15 - 20150079077 - The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present...

Biomarkers for triple negative breast cancer
03/19/15 - 20150079078 - The present invention relates to biomarkers that are useful in the prognosis of triple negative breast cancer patients. The biomarkers may be used to select treatment and to determine whether a treatment is effective or not. The biomarkers may also be used to select novel treatments and to screen for...

Methods and compositions for treatment of chlamydial infection and related diseases and disorders
03/19/15 - 20150079079 - The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject....

Novel anti-igf-ir antibodies and uses thereof
03/19/15 - 20150079080 - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic...

Tricyclic p13k inhibitor compounds and methods of use
03/19/15 - 20150079081 - Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described....

Optimized fc variants and methods for their generation
03/19/15 - 20150079082 - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants....

Biomarkers and methods of treating pd-1 and pd-l1 related conditions
03/12/15 - 20150071910 - Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods...

Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
03/12/15 - 20150071911 - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus....

Prophylaxis of colorectal and gastrointestinal cancer
03/12/15 - 20150071912 - The present disclosure provides methods and compositions useful for preventing gastrointestinal and/or colorectal cancer in animals, including humans, having pre-cancerous adenomatous polyps. The present disclosure provides compositions comprising anti-PG antibodies suitable for use in the methods of the disclosure. The present disclosure also provides methods and compositions useful for monitoring...

Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
03/12/15 - 20150071913 - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited...

Methods of treatment using ctla4 mutant molecules
03/12/15 - 20150071914 - The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33...

Monoclonal antibodies against amyloid beta protein and uses thereof
03/12/15 - 20150071915 - The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders....

Anti-cd28 humanized antibodies
03/12/15 - 20150071916 - The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through...

Methods and products for evaluating an immune response to a therapeutic protein
03/12/15 - 20150071917 - The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding...

Peptides for the treatment of cancer
03/12/15 - 20150071918 - The invention relates to novel cyclic compounds (cyclic peptides), linkers useful as beta-turn promoters in cyclic peptides, and methods for treatment of malignant cells in vitro or in vivo using one or more linear and cyclic peptides. The peptides can act as integrin interaction inhibitors and may be used in...

Cancer therapy
03/12/15 - 20150071919 - The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Patients to be treated include those that have been treated...

Liquid protein formulations containing water soluble organic dyes
03/12/15 - 20150071920 - Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering water soluble organic dyes....

Liquid protein formulations containing organophosphates
03/12/15 - 20150071921 - Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is...

Liquid protein formulations containing ionic liquids
03/12/15 - 20150071922 - Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids....

Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
03/12/15 - 20150071923 - Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies....

Anti-angiogenesis therapy for the treatment of previously treated breast cancer
03/12/15 - 20150071924 - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, in combination with one or more additional anti-tumor therapeutic agents in previously treated metastatic breast cancer....

Combinations of akt inhibitor compounds and chemotheraeptuc agents, and methods of use
03/05/15 - 20150064171 - The invention provides combinations comprising a) compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38,...

Methods of treating a disease or disorder associated with bruton's tyrosine kinase
03/05/15 - 20150064172 - The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK....

Methods of treating a disease or disorder associated with bruton's tyrosine kinase
03/05/15 - 20150064173 - The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK....

Neutralizing antibody for epstein barr virus-associated disease
03/05/15 - 20150064174 - Described herein are compositions, methods, and uses relating to an EBV-neutralizing antibody....

Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic
03/05/15 - 20150064175 - A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one, is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as...

Methods for treating conditions associated with masp-2 dependent complement activation
03/05/15 - 20150064176 - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2...

Therapeutic uses of humanized antibodies against alpha-4 integrin
03/05/15 - 20150064177 - The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated...

Diagnostic methods and compositions for treatment of glioblastoma
03/05/15 - 20150064178 - The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods....

Humanized anti-il 10 antibodies for the treatment of systemic lupus erythematosus (sle)
03/05/15 - 20150064179 - Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (1L-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving...

Combination therapy with cd4 lymphocyte depletion and mtor inhibitors
03/05/15 - 20150064180 - The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of...

Therapeutic canine immunoglobulins and methods of using same
02/26/15 - - A method of preparing a canine antibody suitable for use in the therapeutic treatment of a canine is provided. In particular, there is provided immunoglobulins which can be selected for the characteristic of whether they mediate downstream complement mediated immune activation when bound to a target antigen. Canine derived antibodies...

Protein belonging to the tnf superfamily involved in signal transduction, nucleic acids encoding same and methods of use thereof
02/26/15 - 20150056184 - A method of modulating immune response in an animal is disclosed. Such a method interacting the immature dendritic cells from the animal with an antigen ex vivo so that the immature dendritic cells present the antigen on their surfaces, inducing maturation of the immature dendritic cells ex vivo, and contacting...

Immunoglobulin constant region fc receptor binding agents
02/26/15 - 20150056185 - IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are...

Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
02/26/15 - 20150056186 - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2...

Humanized antibodies that recognize alpha-synuclein
02/26/15 - 20150056187 - The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease....

Jcv neutralizing antibodies
02/26/15 - 20150056188 - In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-virus. In some...

Cdr-modified anti-siglec-15 antibody
02/26/15 - 20150056189 - Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like....

Diagnostic methods and compositions for treatment of cancer
02/26/15 - 20150056190 - The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods....

Igf1 biomarker for igf1r inhibitor therapy
02/26/15 - 20150056191 - The present invention provides, inter alia, methods for treating tumors that are sensitive to an IGF1R inhibitor. The tumor are determined to be sensitive if the level of IGF1 mRNA expression in the tumor cells, relative to one or more reference genes, reaches a certain threshold level. Methods for evaluating...

Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
02/26/15 - 20150056192 - The invention provides for compositions for treating a cancer or an inflammatory disorder comprising a combination of agents in a pharmaceutically acceptable carrier, wherein said agents comprise: (i) a non-covalent DNA binding agent; and (ii) an anti-cancer or anti-inflammatory agent....

Egfr and ros1 kinase in cancer
02/26/15 - 20150056193 - The present disclosure provides methods of that include detecting in a biological sample from a patient having or suspected of having cancer the presence of a polypeptide having ROS1 kinase activity or a polynucleotide encoding the same and detecting in the biological sample the presence of a mutant EGFR polypeptide...

Modified green tea polyphenols and methods thereof for treating liver disease
02/26/15 - 20150056194 - Methods of treating liver disease in a subject, including administering to the subject an effective amount of one or more modified green tea polyphenols to reduce, decrease, limit or prevent one or more symptoms of liver disease relative to an untreated control subject are provided. In a preferred embodiment the...

Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
02/26/15 - 20150056195 - The invention relates to the field of oncology and to chemotherapy resistance and relapse. Thus the invention provides compositions and methods for inhibiting tumorigenicity of senescent cancer cells induced by a chemotherapeutic agent. The invention also provides compositions and methods for inhibiting conversion of non-stem cancer cells (non-CSCs) into tumor...

Antibody purification by cation exchange chromatography
02/26/15 - 20150056196 - A method for purifying an antibody by cation exchange chromatography is described in which a high pH wash step is used to remove of contaminants prior to eluting the desired antibody using an elution buffer with increased conductivity....

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
02/19/15 - - This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA...

Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
02/19/15 - 20150050267 - The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described....

Prolonged inhibition of interleukin-6 mediated signaling
02/19/15 - - Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that...

Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
02/19/15 - 20150050269 - The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as...

Antibodies to bradykinin b1 receptor ligands
02/19/15 - 20150050270 - The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin...

Jcv neutralizing antibodies
02/19/15 - 20150050271 - In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some...

Method of dynamic spectroscopy under physiological conditions
02/19/15 - 20150050272 - The present invention relates to the field of dynamic spectroscopy and more precisely to a method involving dynamic molecules spectroscopy technology designed to determine transitional changes in molecules conformation and assemblies both in physiologic and pathologic conditions. The method comprises in vitro fingerprints of a sample taken under highly controlled...

Afucosylated anti-fgfr2iiib antibodies
02/19/15 - 20150050273 - The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided....

Methods and biomarkers for detection and treatment of mature t-cell leukemia
02/19/15 - 20150050274 - The present invention relates to methods and biomarkers for detection and characterization of mature T-cell neoplasias/leukemias (e.g., T-cell prolymphocytic leukemia, Sezary syndrome) in biological samples (e.g., tissue samples, blood samples, plasma samples, cell samples, serum samples)....

Purification of anti-c-met antibodies
02/19/15 - 20150050275 - Provided herein are methods of purifying anti-c-met antibodies, compositions and pharmaceutical formulations comprising purified anti-c-met antibodies, and methods of using the same....

High affinity antibodies that neutralize staphylococcus enterotoxin b
02/19/15 - 20150050276 - Provided herein are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B....